Navigating treatment resistance: Janus kinase inhibitors for ulcerative colitis

doi:10.12998/wjcc.v12.i24.5468

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 24

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1863)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series.

Item

Count

PDF

152

HTML

1133

Figures (1-3)

202

Sum=1487

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

193

Sum=278

Aug 26, 2024 (publication date) through Feb 24, 2025

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Clin Cases. Aug 26, 2024; 12(24): 5468-5472
Published online Aug 26, 2024. doi: 10.12998/wjcc.v12.i24.5468

Full Size Figure Download Figure

Figure 3 Colonoscopy. Maintenance therapy with infliximab, three years after tofacitinib was withdrawn. Scarred mucosa, Mayo endoscopic score 0. A: Transition zone in the transverse colon; B: Sigmoid colon.

Citation: Soldera J. Navigating treatment resistance: Janus kinase inhibitors for ulcerative colitis. World J Clin Cases 2024; 12(24): 5468-5472
URL: https://www.wjgnet.com/2307-8960/full/v12/i24/5468.htm
DOI: https://dx.doi.org/10.12998/wjcc.v12.i24.5468